On Oct 26, major Wall Street analysts update their ratings for $ResMed (RMD.US)$, with price targets ranging from $245 to $283.
J.P. Morgan analyst David Low maintains with a buy rating, and adjusts the target price from $240 to $270.
BofA Securities analyst Lyanne Harrison maintains with a buy rating.
Jefferies analyst Matthew Taylor maintains with a hold rating, and adjusts the target price from $164 to $245.
Baird analyst David Rescott maintains with a buy rating, and adjusts the target price from $280 to $283.
Oppenheimer analyst Suraj Kalia maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $ResMed (RMD.US)$'s main analysts recently are as follows:
Following the Q1 earnings report, there is encouragement from the broad outperformance expected to begin in fiscal 2025, with a particular focus on the trends in Devices amidst ongoing GLP-1 concerns. Additionally, the company is on a path to lower its debt, thus enhancing its capital allocation flexibility.
ResMed demonstrated robust first quarter results, featuring double-digit revenue expansion across all segments, continued enhancement of gross margins, and a 35% increase in EPS. Management's outlook remains optimistic due to overall industry growth, consistent resupply activities, and prospects for further gross margin advancements.
The firm expressed growing confidence in potential upside, noting that market growth is holding steady, the company is maintaining or even expanding its market share, and is seeing advantages from the broader deployment of its AirSense 11 product.
Here are the latest investment ratings and price targets for $ResMed (RMD.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月26日，多家華爾街大行更新了$瑞思邁 (RMD.US)$的評級，目標價介於245美元至283美元。
摩根大通分析師David Low維持買入評級，並將目標價從240美元上調至270美元。
美銀證券分析師Lyanne Harrison維持買入評級。
富瑞集團分析師Matthew Taylor維持持有評級，並將目標價從164美元上調至245美元。
貝雅分析師David Rescott維持買入評級，並將目標價從280美元上調至283美元。
奧本海默控股分析師Suraj Kalia維持持有評級。
此外，綜合報道，$瑞思邁 (RMD.US)$近期主要分析師觀點如下：
在Q1業績報告之後，預計從2025財年開始將出現廣泛超額表現，特別關注GLP-1問題持續存在的設備趨勢。此外，公司正致力於減少債務，提升資本配置靈活性。
瑞思邁展示了強勁的第一季度業績，所有板塊營業收入持續擴張，毛利率持續提升，並且每股收益增長35%。管理層的展望仍然樂觀，原因是整體行業增長、持續的補給活動以及進一步提升毛利率的前景。
公司對潛在上行增長表達了增強的信懇智能，指出市場增長保持穩定，公司正在維持甚至擴大市場份額，並從其AirSense 11產品更廣泛部署中獲得優勢。
以下爲今日5位分析師對$瑞思邁 (RMD.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
